RxDoctor Payments Data

Fernando Ariza, MD

Internal Medicine · Winston Salem, NCNPI 1699750638

Payments from drug & device makers

$1,681in general payments, 2019–2025

Across 59 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$574
  • AstraZeneca$279
  • Boehringer Ingelheim$181
  • Otsuka America Pharmaceutical, Inc.$89
  • Calliditas Therapeutics US Inc.$77
  • Fresenius USA Marketing, Inc.$71
  • plus $411 from 9 others

What the payments were for

  • Travel & lodging$22113%
  • Food & beverage$1,44086%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,681 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,773
Medicare patients
115
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin141$154,073
FarxigaDapagliflozin Propanediol48$46,108
KerendiaFinerenone25$30,702
Clonidine11$1,137
Chlorthalidone49$790
ValacyclovirValacyclovir Hcl13$613
Amlodipine Besylate57$368
Duloxetine Hcl15$315
Losartan Potassium23$304
Lisinopril53$254
Labetalol Hcl14$246
Pravastatin Sodium11$177
Nifedipine ErNifedipine17$172
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril12$138
Spironolactone14$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$181$154,073141 claims
AstraZenecaFarxiga$279$46,10848 claims
BayerKerendia$68$30,70225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →